Compare Enveric Biosciences Inc (ENVB) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Vanguard International High Dividend Yield ETF trades at $100.25 (market cap $22.80B). The key difference: Vanguard International High Dividend Yield ETF is far larger — about 3352.9× Enveric Biosciences Inc's market cap, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| ENVB | VYMI | |
|---|---|---|
Market Cap | $6.80M | $22.80B |
Volume | 64,867 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $107.13 |
52-Week Low | $1.27 | $82.92 |
Typical Hold Time | 14 Days | 50 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
VYMI trades at $100.23, down 1.11% today amid bearish technical signals. The ETF shows strong institutional interest with multiple firms increasing holdings recently. Recent analysis highlights VYMI's 5-year average annual return of 14.13% and 3.61% dividend yield, outperforming peers despite current technical weakness.
The outlook remains positive given VYMI's exposure to international dividend stocks benefiting from higher global rates. Key risks include currency fluctuations and concentrated financial sector exposure. Analyst sentiment leans bullish with expectations of continued international stock outperformance versus US markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
